CardioMotion: identification of functional and structural cardiotoxic liabilities in small molecules through brightfield kinetic imaging
Toxicological Sciences · 2023
DOI: 10.1093/toxsci/kfad065 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxicological Sciences, 2023. Verfasst von William Stebbeds und 13 weiteren Autor:innen. Beteiligte Einrichtung: Screening Profiling and Mechanistic Biology, GSK, Stevenage, SG1 2NY, UK. Hauptthemen laut MEDLINE: Cardiotoxicity, Induced Pluripotent Stem Cells. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: GSK.
Abstract (Originalsprache)
Cardiovascular toxicity is an important cause of drug failures in the later stages of drug development, early clinical safety assessment, and even postmarket withdrawals. Early-stage in vitro assessment of potential cardiovascular liabilities in the pharmaceutical industry involves assessment of interactions with cardiac ion channels, as well as induced pluripotent stem cell-derived cardiomyocyte-based functional assays, such as calcium flux and multielectrode-array assays. These methods are appropriate for the identification of acute functional cardiotoxicity but structural cardiotoxicity, which manifests effects after chronic exposure, is often only captured in vivo. CardioMotion is a novel, label-free, high throughput, in vitro assay and analysis pipeline which records and assesses the spontaneous beating of cardiomyocytes and identifies compounds which impact beating. This is achieved through the acquisition of brightfield images at a high framerate, combined with an optical flow-based python analysis pipeline which transforms the images into waveform data which are then parameterized. Validation of this assay with a large dataset showed that cardioactive compounds with diverse known direct functional and structural mechanisms-of-action on cardiomyocytes are identified (sensitivity = 72.9%), importantly, known structural cardiotoxins also disrupt cardiomyocyte beating (sensitivity = 86%) in this method. Furthermore, the CardioMotion method presents a high specificity of 82.5%.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Screening Profiling and Mechanistic Biology, GSK, Stevenage, SG1 2NY, UK.
- The Biodiscovery Institute, University of Nottingham, Nottingham, NG7 2RD, UK.
- In vitro in vivo translation, GSK, Upper Providence, PA 19426, USA.
- In vitro in vivo translation, GSK, Ware, SG12 0DJ, UK.
ORCID-Profile: William Stebbeds, Kavita Raniga, David Standing, Iona Wallace, James Bayliss, Andrew Brown, Richard Kasprowicz, Deidre Dalmas Wilk, Julianna Deakyne, Peter Clements, Khuram W Chaudhary, Eric I Rossman, Anthony Bahinski, Jo Francis
Förderung
- GSK
Zitieren
APA
Stebbeds, W., Raniga, K., Standing, D., Wallace, I., Bayliss, J., Brown, A., Kasprowicz, R., Dalmas Wilk, D., Deakyne, J., Clements, P., Chaudhary, K. W., Rossman, E. I., Bahinski, A., & Francis, J. (2023). CardioMotion: identification of functional and structural cardiotoxic liabilities in small molecules through brightfield kinetic imaging. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfad065
Vancouver
Stebbeds W, Raniga K, Standing D, Wallace I, Bayliss J, Brown A, et al. CardioMotion: identification of functional and structural cardiotoxic liabilities in small molecules through brightfield kinetic imaging. Toxicological Sciences. 2023. doi:10.1093/toxsci/kfad065
BibTeX
@article{Stebbeds2023,
author = {Stebbeds, William and Raniga, Kavita and Standing, David and Wallace, Iona and Bayliss, James and Brown, Andrew and Kasprowicz, Richard and Dalmas Wilk, Deidre and Deakyne, Julianna and Clements, Peter and Chaudhary, Khuram W and Rossman, Eric I and Bahinski, Anthony and Francis, Jo},
title = {CardioMotion: identification of functional and structural cardiotoxic liabilities in small molecules through brightfield kinetic imaging},
journal = {Toxicological Sciences},
year = {2023},
doi = {10.1093/toxsci/kfad065}
}
EUVIMED